Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

`Unacceptable discrepancies' in UK funding of Alzheimer's drugs

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    `Unacceptable discrepancies' in UK funding of Alzheimer's drugs. Pharmacoecon. Outcomes News 304, 2 (2001). https://doi.org/10.1007/BF03280208

    Download citation

    Keywords

    • Outcome News
    • National Health Service
    • Acetylcholinesterase
    • Health Authority
    • Clinical Excellence